CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, Anders Osterborg, Marek Trneny, Lois Shepherd, Devinder S Gill, Jan Walewski, Ruth Pettengell, Ulrich Jaeger, Pier-Luigi Zinzani, Ofer Shpilberg, Stein Kvaloy, Peter de Nully Brown, Rolf Stahel, Noel Milpied, Armando López-Guillermo, Viola Poeschel, Sandra Grass, Markus LoefflerNiels Murawski, MabThera International Trial (MInT) Group

    634 Citationer (Scopus)

    Abstract

    The MInT study was the first to show improved 3-year outcomes with the addition of rituximab to a CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimen in young patients with good-prognosis diffuse large-B-cell lymphoma. Extended follow-up was needed to establish long-term effects.
    OriginalsprogEngelsk
    TidsskriftLancet Oncology
    Vol/bind12
    Udgave nummer11
    Sider (fra-til)1013-22
    Antal sider10
    ISSN1470-2045
    DOI
    StatusUdgivet - 2011

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group'. Sammen danner de et unikt fingeraftryk.

    Citationsformater